|Ms. Valerie Barber Palmieri||Chief Exec. Officer, Pres and Director||450.68k||N/A||56|
|Mr. Eric J. Schoen||Chief Accounting Officer and Sr. VP of Fin.||280.68k||N/A||49|
|Mr. Fred Ferrara||Chief Operating Officer||354.87k||N/A||49|
|Dr. Marra Francis M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Patrick Carpenter||Gen. Mang. of ASPiRA LABS||N/A||N/A||N/A|
Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women in the United States. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The companys products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
Vermillion, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.